- Fulgent Genetics, founded in 2011, specializes in precision medicine and genetic testing, with a market position bolstered by a 14% year-over-year revenue increase, reaching $322.7 million in 2025.
- In 2025, Fulgent announced its acquisition of Bako Diagnostics and StrataDx for approximately $56 million, aimed at diversifying revenue streams and reducing reliance on a single customer, which is expected to contribute an additional $50-55 million in revenue.
- The company serves a diverse clientele, including healthcare providers and laboratories, and is transitioning to a more integrated model as its largest customer shifts testing in-house, which will impact revenue significantly in 2026.
- Fulgent's ideal buyers are healthcare institutions seeking advanced genetic testing solutions, particularly in oncology, as the company enhances its offerings with AI-driven digital pathology tools to expedite diagnostics and improve patient outcomes.
Engineering is the largest function at Fulgent Genetics, housing around 120 employees and making up just over two-fifths of the workforce. Sales & Support and Healthcare teams combine for roughly one-fifth of staff, reflecting the company’s focus on customer engagement and clinical expertise. Supporting functions—Finance & Administration, Business Management, Human Resources, Operations, Legal, and other smaller groups—collectively form the remaining share, ensuring corporate governance and operational efficiency. The departmental spread signals a research-driven culture buttressed by targeted go-to-market efforts and lean administrative teams.
Fulgent Genetics operates a dispersed U.S. footprint that blends regional hubs with a significant remote presence. The largest cluster is in the greater Los Angeles area, which hosts a little more than one-quarter of employees, while a comparable portion is classified as remote or at unspecified locations. Additional teams are based in Houston, San Diego, New York, and several smaller Southern California cities, each supporting specialized laboratory or client-facing functions. This hybrid model enables the company to access diverse talent pools and serve customers nationwide.
